Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Sami Shoucair

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3506-734X; OpenAlex author ID A5031819991. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2021: 1 paper · 2022: 7 papers · 2023: 4 papers · 2024: none · 2025: 2 papers

Papers 14

  1. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  2. Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer. Co-author DOI 10.1186/s40364-024-00721-7↗
  3. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal A… Co-author DOI 10.1001/jamasurg.2022.4976↗
  4. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. First author DOI 10.1007/s11605-022-05476-w↗
  5. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. First author DOI 10.1097/js9.0000000000000200↗
  6. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Co-author DOI 10.1245/s10434-022-12901-6↗
  7. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Co-author DOI 10.1001/jamasurg.2022.1362↗
  8. Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/ags3.12514↗
  9. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  10. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mco2.184↗
  11. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. First author DOI 10.1007/s00268-022-06667-x↗
  12. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  13. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an In… Co-author DOI 10.1245/s10434-021-11081-z↗
  14. Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-021-06209-x↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Yu · 9 shared papers, 2021–2023 · strength 1.60
  2. Jin Peng He · 9 shared papers, 2021–2023 · strength 1.25
  3. Joseph R. Habib · 8 shared papers, 2021–2025 · strength 1.17
  4. Kelly J. Lafaro · 7 shared papers, 2021–2023 · strength 0.97
  5. Benedict Kinny‐Köster · 6 shared papers, 2021–2023 · strength 0.83
  6. William R. Burns · 6 shared papers, 2021–2023 · strength 0.80
  7. Richard Andrew Burkhart · 6 shared papers, 2021–2023 · strength 0.80
  8. Ning Pu · 5 shared papers, 2022–2025 · strength 0.78
  9. Lei Zheng · 4 shared papers, 2022–2025 · strength 0.64
  10. Christopher R. Shubert · 4 shared papers, 2022–2023 · strength 0.58
  11. Christopher Lee Wolfgang · 4 shared papers, 2021–2023 · strength 0.56
  12. Ammar A. Javed · 4 shared papers, 2021–2023 · strength 0.55
  13. Christopher L. Wolfgang · 4 shared papers, 2022–2023 · strength 0.55
  14. Hanlin Yin · 2 shared papers, 2022–2025 · strength 0.34
  15. Qiangda Chen · 2 shared papers, 2022–2025 · strength 0.34
  16. Shanshan Gao · 2 shared papers, 2022–2025 · strength 0.34
  17. Elie M. Ghabi · 2 shared papers, 2023 · strength 0.30
  18. A. Floortje van Oosten · 2 shared papers, 2022 · strength 0.28
  19. Eun Ji Shin · 2 shared papers, 2022–2023 · strength 0.27
  20. Mengni He · 1 shared paper, 2025 · strength 0.21
  21. Brian T. Herbst · 1 shared paper, 2025 · strength 0.21
  22. Nan Niu · 1 shared paper, 2025 · strength 0.21
  23. Keyu Li · 1 shared paper, 2025 · strength 0.21
  24. Jun-Ke Wang · 1 shared paper, 2025 · strength 0.21
  25. Yiping Mou · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.